Opdivo® (nivolumab) – Indication withdrawal
July 23, 2021 - Bristol Myers Squibb announced that the company plans to voluntarily withdraw the indication for Opdivo (nivolumab) as a single agent for patients with hepatocellular carcinoma (HCC) who were previously treated with Nexavar® (sorafenib).
Download PDF
